Among the encouraging results, relative to 2007: a) there was a major increase in the number of recombinant proteins; b) 2008 new products are expected to collectively attain significantly higher peak sales levels; and c) more products came from smaller U.S. biotech-type and U.S.-based vs. large pharmaceutical and foreign companies.